|
|
| | BMS-265246 Basic information |
| Product Name: | BMS-265246 | | Synonyms: | BMS-265246;BMS-265246, >=98%;(4-Butoxy-1H-pyrazolo[3,4-b]pyridin-5-yl)(2,6-difluoro-4-methylphenyl)-methanone;(4-Butoxy-1H-pyrazolo[3,4-b]pyridin-5-yl)(2,6-difluoro-4-methylphenyl)-methanone BMS265246;BMS265246; BMS 265246;CS-984;Methanone, (4-butoxy-1H-pyrazolo[3,4-b]pyridin-5-yl)(2,6-difluoro-4-methylphenyl)-;BMS-265246 USP/EP/BP | | CAS: | 582315-72-8 | | MF: | C18H17F2N3O2 | | MW: | 345.34 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 582315-72-8.mol |  |
| | BMS-265246 Chemical Properties |
| Boiling point | 552.9±50.0 °C(Predicted) | | density | 1.304±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | insoluble in H2O; insoluble in EtOH; ≥17.25 mg/mL in DMSO | | form | solid | | pka | 8.50±0.40(Predicted) | | color | White to pink |
| | BMS-265246 Usage And Synthesis |
| Uses | BMS-265246 is a potent and selective pyra-zolopyridine based inhibitor of cdk2/cyclinE, cdk1/cyclinB and cdk4/ cyclinD. | | Biological Activity | bms265246 is a potent and selective inhibitor for cdk1 and cdk2 (ic50= 6 nm and 9 nm)cyclin-dependent kinases (cdk) are a group of serine/threonine kinases. they are activated by coupling to cyclin and participate in the regulation of cell cycle.bms265246 inhibited the cdk4/cycd activity and prevented a2780 cytox (ic50 = 0.23 μm and 0.76 μm) [1]. in hct-116 cells, bms-265246 blocked the cell proliferation (ec50= 0.293 μm—0.492 μm). following the treatment of bms-265246, low dna intensity, large round nuclei and 4n dna content were observed in the dominant cell population –g2 arrested cells. [2] | | storage | Store at -20°C | | references | 1. misra rn, xiao hy, rawlins db et al. 1h-pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases: highly potent 2,6-difluorophenacyl analogues. bioorgmed chem lett. 2003 jul 21;13(14):2405-8.2. sutherland jj, low j, blosser w et al. a robust high-content imaging approach for probing the mechanism of action and phenotypic outcomes of cell-cycle modulators. mol cancer ther. 2011 feb;10(2):242-54. |
| | BMS-265246 Preparation Products And Raw materials |
|